In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
The closing price of Gain Therapeutics Inc (NASDAQ: GANX) was $3.19 for the day, up 10.96% from the previous closing price of $2.88. In other words, the price has increased by $10.96 from its previous closing price. On the day, 2.91 million shares were traded. GANX stock price reached its highest trading level at $3.3 during the session, while it also had its lowest trading level at $2.75.
Ratios:
Our analysis of GANX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.52 and its Current Ratio is at 2.52. In the meantime, Its Debt-to-Equity ratio is 0.10 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In the most recent recommendation for this company, Scotiabank on March 07, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $12.
On December 06, 2024, ROTH MKM started tracking the stock assigning a Buy rating and target price of $7.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GANX now has a Market Capitalization of 122694048 and an Enterprise Value of 106949064.
Stock Price History:
The Beta on a monthly basis for GANX is 0.08, which has changed by 0.80817616 over the last 52 weeks, in comparison to a change of 0.13153219 over the same period for the S&P500. Over the past 52 weeks, GANX has reached a high of $4.34, while it has fallen to a 52-week low of $1.41. The 50-Day Moving Average of the stock is 17.32%, while the 200-Day Moving Average is calculated to be 55.93%.
Shares Statistics:
GANX traded an average of 1.35M shares per day over the past three months and 3098180 shares per day over the past ten days. A total of 38.46M shares are outstanding, with a floating share count of 37.07M. Insiders hold about 3.62% of the company’s shares, while institutions hold 11.29% stake in the company. Shares short for GANX as of 1764288000 were 1260732 with a Short Ratio of 0.93, compared to 1761868800 on 910705. Therefore, it implies a Short% of Shares Outstanding of 1260732 and a Short% of Float of 3.3800002000000005.
Earnings Estimates
. The current rating of Gain Therapeutics Inc (GANX) is the result of assessments by 4.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.13 and low estimates of -$0.19.
Analysts are recommending an EPS of between -$0.63 and -$0.66 for the fiscal current year, implying an average EPS of -$0.64. EPS for the following year is -$0.71, with 4.0 analysts recommending between -$0.55 and -$0.95.
